Mr. Ellberger was appointed Chairman of the Board of Directors of Celldex in September 2009. Mr. Ellberger has been an independent member of the Celldex Board of Directors since the merger in March 2008 between Celldex and AVANT Immunotherapeutics and had been a director of AVANT since 2003. From 2003 to July 2012, he was Founding Partner of HVA, a consulting firm specializing in business development, product acquisition and licensing, and mergers and acquisitions for pharmaceutical, biotechnology, drug delivery and medical device companies. He served as Chairman of the Board of Omrix Biopharmaceuticals until its acquisition by Johnson & Johnson in 2008. From October 2005 to May 2016, Mr. Ellberger was interim Chief Executive Officer of PDI, where he had been serving as a Director and Chairman of the Audit Committee. Mr. Ellberger was a Board member and Senior Vice President of Powderject plc from 2000 to 2003. From 1995 to 1999, Mr. Ellberger was an officer of W.R. Grace & Co., serving as interim Chief Executive Officer, Chief Financial Officer and Senior Vice President, Strategic Planning and Development. From 1975 to 1995, Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. Mr. Ellberger is a director of NeuroDerm, a NASDAQ-listed Israeli biotech company, and is a member of its audit and nominating committees. He is also a director of The Jewish Children’s Museum. He received a B.A. in economics from Columbia College and a B.Sc. in Chemical Engineering from Columbia School of Engineering.
Keith L. Brownlie
Former Partner, Ernst & Young LLP
Mr. Brownlie has been a director of Celldex since June 2017. He was employed by the accounting firm Ernst & Young LLP from 1974 to 2010, where he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York metropolitan area. He currently serves as a member of the boards of directors and chairman of the audit committees for two publicly-held biopharmaceutical companies—Soligenix, Inc. and RXi Pharmaceuticals Corporation, and he previously served in the same capacity for the publicly-held EpiCept Corporation and Cancer Genetics, Inc. Mr. Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.
Herbert J. Conrad
Former President, Roche Pharmaceuticals US
Mr. Conrad has been a director of Celldex since March 2004. He was President of Roche Pharmaceuticals in the United States from 1982 until his retirement in 1993. Mr. Conrad currently serves as Chairman of the Board of Matinas BioPharma Holdings, as a director of Arbutus Biopharmaceuticals and as an advisor to the Seaver Autism Center at Mount Sinai Hospital. He previously served as Chairman of Pharmasset, GenVec and Bone Care International, and he served as a director of Savient Pharmaceuticals and Reliant Pharmaceuticals, where he was a co-founder. Mr. Conrad received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary doctorate in humane letters from Long Island University.
James J. Marino, J.D.
Former Partner, Dechert LLP
Mr. Marino has been a director of Celldex since March 2017. He was with the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office. His practice focused on the representation of leading life sciences companies, both privately- and publicly-held, in a broad range of corporate, transactional and finance matters. Mr. Marino currently serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center and on the Board of Directors of Onconova Therapeutics, Inc. He previously served on the Board of Directors of Pharmacopeia, Inc. He has also worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. Additionally, Mr. Marino is a co-founder of BioNJ, the trade association of biotechnology companies based in New Jersey, which he represented from its inception. Mr. Marino received his B.A., his M.B.A. and his J.D. from Rutgers University.
Anthony S. Marucci
Founder, President, Chief Executive Officer and Director
Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (now a part of Bristol-Myers Squibb), was spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for Celldex’s merger with AVANT Immunotherapeutics completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci is a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci received a B.S. in Accounting from Kean University, an MBA from Columbia University and an Executive Master of Healthcare Leadership (EMHL) from Brown University.
Gerald McMahon, Ph.D.
Former President and CEO, Kolltan Pharmaceuticals
Dr. McMahon has been a director of Celldex since December 2016. He was previously the President and Chief Executive Officer of Kolltan Pharmaceuticals. Prior to joining Kolltan, Dr. McMahon served as Senior Vice President, R&D Oncology at MedImmune, where he oversaw the strategy and investment for the oncologic biologics pipeline. Prior to joining MedImmune, Dr. McMahon was a Venture Partner at Bay City Capital. Previously, he held roles including that of Chairman and CEO of Poniard Pharmaceuticals, CEO and President of NeoRx and President at SUGEN, where he played a critical role in the successful discovery, development, and regulatory approvals of Sutent® and Palladia®. Dr. McMahon also was a Director at Sandoz, serving in various research and development roles. Dr. McMahon received his B.S. in Biology and Ph.D. in Biochemistry from Rensselaer Polytechnic Institute. He has held academic appointments at the Tufts University School of Medicine, Department of Hematology & Oncology at the New England Medical Center, and the Massachusetts Institute of Technology.
Harry H. Penner, Jr., J.D., L.L.M.
Chairman and CEO, Nascent Bioscience
Mr. Penner has been a director of Celldex since the merger in March 2008 between Celldex and AVANT Immunotherapeutics and had been a director of AVANT since January 1997. In 2001, he founded Nascent BioScience, a firm engaged in the creation and development of new biotechnology companies, where he is currently Chairman and Chief Executive Officer. From 1993 to 2001, Mr. Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President and General Counsel in Denmark. In addition to having served on the board of directors of several public and privately held life science companies, Mr. Penner is currently on the Board of Directors of Prevention Pharmaceuticals, Affinimark Technologies, Neurovail and Aria Neurosciences. He has served as BioScience Advisor to the Governor and the State of Connecticut, Co-Chair of Connecticut United for Research Excellence, Chair of the Connecticut Board of Governors of Higher Education and Chair of the Connecticut Technology Council. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University and an L.L.M. in International Law from New York University.
Karen L. Shoos, J.D.
Consultant, AABB International Technical Assistance, Division of Global Services
Ms. Shoos has been a director of Celldex since the merger in March 2008 between Celldex and AVANT Immunotherapeutics and had been a director of AVANT since May 2001. From May 2013 to September 2016, Ms. Shoos was Principal Investigator, AABB International Technical Assistance, a professional standards setting and accrediting organization in the fields of blood and cellular therapies, and from 1994 to 2013, she was the Chief Executive Officer. From 1984 to 1994, she held senior positions at the American Red Cross, including Acting Senior Vice President, Biomedical Services, as well as General Counsel and Secretary. Prior to the American Red Cross, Ms. Shoos was a lawyer in private practice. She received her B.A. from Yale University and J.D. from Case Western Reserve University.